Get the Stockscreener App
0.72
4.67%
-0.0353
After Hours:
.69
-0.03
-4.17%
Scisparc Ltd stock is traded at $0.72, with a volume of 742.10K.
It is down -4.67% in the last 24 hours and up +214.41% over the past month.
SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
See More
Previous Close:
$0.7553
Open:
$0.7421
24h Volume:
742.10K
Relative Volume:
0.09
Market Cap:
$7.80M
Revenue:
$1.75M
Net Income/Loss:
$-5.68M
P/E Ratio:
-0.1478
EPS:
-4.8726
Net Cash Flow:
-
1W Performance:
-10.74%
1M Performance:
+214.41%
6M Performance:
-9.89%
1Y Performance:
-81.30%
1-Day Range:
$0.68
$0.7601
1-Week Range:
$0.63
$0.909
52-Week Range:
$0.197
$6.78
Scisparc Ltd Stock (SPRC) Company Profile
Compare SPRC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRC
Scisparc Ltd
|
0.72 | 7.80M | 1.75M | -5.68M | 0 | -4.8726 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.96 | 107.38B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.23 | 76.18B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
659.81 | 39.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
249.16 | 32.14B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
112.76 | 27.03B | 3.30B | -501.07M | 1.03B | -2.1146 |
Scisparc Ltd Stock (SPRC) Latest News
SciSparc Ltd. Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing - Marketscreener.com
SciSparc, Automax enters direct import market with $13M first shipment of JAC EVs - MSN
SPRCSciSparc Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
SciSparc Granted Nasdaq Compliance Extension - TipRanks
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement - GlobeNewswire
SciSparc Secures Critical Nasdaq Extension to Meet $1 Minimum Bid Requirement - StockTitan
SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles - GlobeNewswire
SciSparc's AutoMax Secures First $13M JAC Motors EV Shipment for Israeli Market Launch - StockTitan
SciSparc says MitoCareX expands research to pancreatic cancer - Yahoo Finance
SciSparc Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 - Marketscreener.com
Scisparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment - Marketscreener.com
SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results - GlobeNewswire
SciSparc's MitoCareX Breakthrough: AI-Powered Platform Shows Promise in Pancreatic Cancer Treatment - StockTitan
SciSparc and Clearmind Medicine Advance with European Patent Application for Psychedelic Binge Behavior Treatment - TipRanks
Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet - Benzinga
Why Is Psychedelic-SciSparc Stock Trading Higher On Monday? - AOL
Stock market today: AEON Biopharma saw gain of 255.62% while SciSparc increased by 89.77% in early trading - Business Upturn
SciSparc-Clearmind Medicine Collaboration Announces the - GlobeNewswire
SciSparc and Clearmind Secure European Patent for Groundbreaking Binge Behavior Treatment - StockTitan
SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment - The Manila Times
IMCA renews SciSparc’s autism spectrum disorder therapy trial approval - Yahoo Finance
SciSparc Secures Approval Renewal for Autism Treatment Trial - TipRanks
SciSparc announces renewal of approval by Israeli Medical Cannabis Agency - TipRanks
SciSparc Announces Renewal of Approval by Israeli Medical - GlobeNewswire
SciSparc Advances Autism Treatment Trial: CBD-Based SCI-210 Gets Key Israeli Approval for Children's Study - StockTitan
Scisparc Ltd. Announces Initiation of Patient Recruitment for Its Clinical Trial with Sci-210 in Children with Autism Spectrum Disorder - Marketscreener.com
SciSparc: AutoMax announces $13M first delivery of JAC vehicles - Yahoo Finance
SciSparc Supports AutoMax’s $13 Million JAC Motors Vehicle Import - TipRanks
S&P 500 Edges Lower, SciSparc Shares SurgeSEALSQ (NASDAQ:LAES), Baosheng Media Gr (NASDAQ:BAOS) - Benzinga
Stock market today: Millennium Group International surged by 318.96% while SciSparc increased by 153.01% in early trading - Business Upturn
SciSparc Shares Skyrocket With AutoMax's First JAC Motors Shipment - Yahoo Finance
SciSparc: AutoMax Announces $13 Million First Delivery of - GlobeNewswire
SciSparc's AutoMax Receives First $13M JAC Motors Shipment Following Israel Import Approval - StockTitan
SciSparc Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 - Marketscreener.com
Scisparc Ltd. with Clearmind Medicine Inc. Publishes for the Innovative Combination of 3,4-Methylenedioxymethamphetamine with N-Acylethanolamines - Marketscreener.com
SciSparc Ltd. Announces Finalize an Exclusive Patent License Agreement with Polyrizon Ltd - Marketscreener.com
Clearmind Medicine Inc. Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment - Marketscreener.com
Scisparc Ltd. and Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy - Marketscreener.com
SciSparc Ltd. Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss - Marketscreener.com
SPRC stock touches 52-week low at $0.21 amid sharp decline - Investing.com Canada
SPRC stock touches 52-week low at $0.21 amid sharp decline By Investing.com - Investing.com South Africa
SciSparc Announces Spin-Off Plans with Miza III Ventures - TipRanks
SciSparc amends non-binding LOI to spin-off advanced clinical stage portfolio - TipRanks
SciSparc Provides Updates on Status of Spin-off of its - GlobeNewswire
SciSparc Advances $11.6M Pharma Portfolio Spin-Off Deal with Miza Ventures, Retaining 84% Control - StockTitan
SciSparc Ltd. to Acquire AutoMax Motors Ltd. - TipRanks
SciSparc Extends Merger Deadline with AutoMax Motors - TipRanks
SciSparc Ltd. Enters into Letter of Intent with Jeffs' Brands Ltd - Marketscreener.com
SciSparc Ltd. Reports Changes in Financial Position - TipRanks
SciSparc Ltd. Gains Shareholder Approval for Proposals - TipRanks
SciSparc Ltd. Reschedules Annual General Meeting - TipRanks
Scisparc Ltd Stock (SPRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.89%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):